

## BAB VII

### DAFTAR PUSTAKA

1. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. *Curr Oncol Rep.* 2012;14(1):48–54.
2. Ostrom QT, Wright CH, Barnholtz-Sloan JS. Brain metastases: epidemiology. 1st ed. Vol. 149, *Handbook of Clinical Neurology*. Elsevier B.V.; 2018. 27–42 p. Available from: <http://dx.doi.org/10.1016/B978-0-12-811161-1.00002-5>
3. Lin X, DeAngelis LM. Treatment of brain metastases. *J Clin Oncol.* 2015;33(30):3475–84.
4. AANS. What Is Stereotactic Radiosurgery, and What Conditions Does It Treat?. American Association of Neurological Surgeons. 2021. Available from: <https://www.aans.org/en/Patients/Neurosurgical-Conditions-and-Treatments/Stereotactic-Radiosurgery>
5. Lee CC, Yen CP, Xu Z, Schlesinger D, Sheehan J. Large intracranial metastatic tumors treated by Gamma Knife surgery: Outcomes and prognostic factors. Clinical article. *J Neurosurg.* 2014;120(1):52–9.
6. Halasz LM, Uno H, Hughes M, D'Amico T, Dexter EU, Edge SB, et al. Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer. *Cancer.* 2016;122(13):2091–100.
7. Koh YW, Choi JH, Ahn MS, Choi YW, Lee HW. Baseline neutrophil-lymphocyte ratio is associated with baseline and subsequent presence of brain metastases in advanced non-small-cell lung cancer. *Sci Rep.* 2016;6(November):1–7. Available from: <http://dx.doi.org/10.1038/srep38585>
8. Ohno Y. Role of systemic inflammatory response markers in urological malignancy. *Int J Urol.* 2019;26(1):31–47.
9. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D, et al. World Health Organization Classification of Tumours WHO Classification of Tumours of the Central Nervous System. Vol. 131,

Acta neuropathologica. 2016. 254–257 p.

10. Femenía T, Magara S, Dupont CM, Lindskog M. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: A population-based study Accepted. 2015;1–28. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26660940>
11. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. *J Clin Oncol.* 2004;22(14):2865–72.
12. Franceschi E, Scopece L, Gori S, Chiari R, Crinò L. Primary and metastatic brain tumors. Vol. 14, FORUM - Trends in Experimental and Clinical Medicine. 2006. Available from: <https://www.cancernetwork.com/view/primary-and-metastatic-brain-tumors>
13. Hall WA, Djalilian HR, Nussbaum ES, Cho KH. Long-term survival with metastatic cancer to the brain. *Med Oncol.* 2000;17(4):279–86.
14. Achrol AS, Rennert RC, Anders C, Soffiatti R, Ahluwalia MS, Nayak L, et al. Brain metastases. *Nat Rev Dis Prim.* 2019;5(1). Available from: <http://dx.doi.org/10.1038/s41572-018-0055-y>
15. Ryken TC, Kuo JS, Prabhu RS, Kalkanis SN, Olson JJ. CONGRESS OF NEUROLOGICAL SURGEONS SYSTEMATIC REVIEW AND EVIDENCE-BASED GUIDELINE ON THE ROLE OF STEROIDS IN THE TREATMENT OF ADULTS WITH METASTATIC BRAIN TUMORS. *Clin Neurosurg.* 2019;1–13.
16. Brian VN, Christopher AB, Priscilla KB, Helen S, Andrew S, Mario A, John SK, Timothy CR, Steven NK, Jeffrey JO. CONGRESS OF NEUROLOGICAL SURGEONS SYSTEMATIC REVIEW AND EVIDENCE-BASED PRACTICE GUIDELINE ON THE ROLE OF SURGERY IN THE MANAGEMENT OF ADULTS WITH METASTATIC BRAIN TUMORS. *Clin Neurosurg.* 2019;iv–iv.
17. Sherman JH, Lo SS, Harrod T, Hdeib A, Li Y, Ryken T, et al. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines

- on the Role of Whole Brain Radiation Therapy in Adults with Newly Diagnosed Metastatic Brain Tumors. *Clin Neurosurg.* 2019;84(3):E175–7.
18. Graber JJ, Cobbs CS, Olson JJ. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Use of Stereotactic Radiosurgery in the Treatment of Adults with Metastatic Brain Tumors. *Clin Neurosurg.* 2019;84(3):E168–70.
  19. Sherman JH, Lo SS, Harrod T, Hdeib A, Li Y, Ryken T, et al. CONGRESS OF NEUROLOGICAL SURGEONS SYSTEMATIC REVIEW AND EVIDENCE-BASED GUIDELINE ON THE ROLE OF CHEMOTHERAPY IN THE MANAGEMENT OF ADULTS WITH NEWLY DIAGNOSED METASTATIC BRAIN TUMORS. *Clin Neurosurg.* 2019;1–39.
  20. Triple-Negative Breast Cancer | CDC. Centers for Disease Control and Prevention. 2020. Available from: <https://www.cdc.gov/cancer/breast/triple-negative.htm>
  21. History and Technical Overview - Neurosurgery. Available from: <https://med.virginia.edu/neurosurgery/services/gamma-knife/for-physicians/history-and-technical-overview/>
  22. Badiyan SN, Regine WF, Mehta M. Stereotactic Radiosurgery for Treatment of Brain Metastases. <https://doi.org/10.1200/JOP2016012922>. 2016 Sep 21;12(8):703–12.
  23. Hamel-Perreault E, Mathieu D, Masson-Cote L. Factors influencing the outcome of stereotactic radiosurgery in patients with five or more brain metastases. *Curr Oncol.* 2019 Feb 1;26(1):e64. Available from: </pmc/articles/PMC6380647/>
  24. Sperduto PW, Shanley R, Luo X, Andrews D, Werner-Wasik M, Valicenti R, et al. Secondary analysis of RTOG 9508, a Phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases; Poststratified by the graded prognostic assessment (GPA). *Int J Radiat Oncol Biol Phys.* 2014;90(3):526–31. Available from: <http://dx.doi.org/10.1016/j.ijrobp.2014.07.002>

25. Bir SC, Ambekar S, Bollam P, Nanda A. Long-term outcome of gamma knife radiosurgery for metastatic brain tumors originating from lung cancer. *Surg Neurol Int.* 2014;5(Suppl 8):S396. Available from: [/pmc/articles/PMC4173307/](#)
26. Kim WH, Kim DG, Han JH, Paek SH, Chung HT, Park CK, et al. Early significant tumor volume reduction after radiosurgery in brain metastases from renal cell carcinoma results in long-term survival. *Int J Radiat Oncol Biol Phys.* 2012;82(5):1749–55.
27. Lee CK, Lee SR, Cho JM, Yang KA, Kim SH. Therapeutic Effect of Gamma Knife Radiosurgery for Multiple Brain Metastases. *J Korean Neurosurg Soc.* 2011;50(3):179. Available from: [/pmc/articles/PMC3218174/](#)
28. Forget P, Khalifa C, Defour J-P, Latinne D, Pel M-C Van, Kock M De. What is the normal value of the neutrophil-to-lymphocyte ratio? *BMC Res Notes.* 2017 Jan 3;10(1):1–4. Available from: [/pmc/articles/PMC5217256/](#)
29. Farkas J. *PulmCrit: Neutrophil-Lymphocyte Ratio (NLR): Free upgrade to your WBC.* 2019. Available from: <https://emcrit.org/pulmcrit/nlr/>
30. Ashwath KG, Aggarwal A, Praneeth K, Singla N, Gupta K. Neutrophil-to-Lymphocyte Ratio: Can It Be Used as an Adjunct Tool to Predict Histopathological Grade of Brain Tumor? *J Neurosci Rural Pract.* 2019;10(4):648. Available from: [/pmc/articles/PMC6906112/](#)
31. Kuranari Y, Tamura R, Tsuda N, Kosugi K, Morimoto Y, Yoshida K, et al. Prognostic Significance of Preoperative Neutrophil-to-Lymphocyte Ratio in Patients With Meningiomas. *Front Oncol.* 2020 Nov 24;0:2601.
32. Cho A, Untersteiner H, Fitschek F, Khalaveh F, Pruckner P, Pavo N, et al. The clinical relevance of laboratory prognostic scores for patients with radiosurgically treated brain metastases of non-pulmonary primary tumor. *J Neurooncol.* 2021 Jul 1;153(3):497. Available from: [/pmc/articles/PMC8279966/](#)
33. Howard R, Scheiner A, Kanetsky PA, Egan KM. Sociodemographic and lifestyle factors associated with the neutrophil-to-lymphocyte ratio. *Ann Epidemiol.* 2019 Oct 1;38:11-21.e6.

34. Howard R, Kanetsky PA, Egan KM. Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. *Sci Reports* 2019 9(1). 2019 Dec 23;9(1):1–10. Available from: <https://www.nature.com/articles/s41598-019-56218-z>
35. Lu A, Li H, Zheng Y, Tang M, Li J, Wu H, et al. Prognostic Significance of Neutrophil to Lymphocyte Ratio, Lymphocyte to Monocyte Ratio, and Platelet to Lymphocyte Ratio in Patients with Nasopharyngeal Carcinoma. *Biomed Res Int.* 2017;2017. Available from: </pmc/articles/PMC5340935/>
36. Grecian R, Whyte MKB, Walmsley SR. The role of neutrophils in cancer. *Br Med Bull.* 2018 Dec 1;128(1):5–14. Available from: <https://academic.oup.com/bmb/article/128/1/5/5077488>
37. Hatiboglu MA, Wildrick DM, Sawaya R. The role of surgical resection in patients with brain metastases. *Ecancermedicalsecience.* 2013 Apr 18;7(1).
38. Walbert T, Gilbert MR. The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. *Int J Clin Oncol.* 2009 Aug;14(4):299–306.
39. Li H, Wang W, Yang X, Lian J, Zhang S, Cao J, et al. The Clinical Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Brain Metastases from Non-Small Cell Lung Cancer-Harboring EGFR Mutations. *Cancer Manag Res.* 2020;12:5659. Available from: </pmc/articles/PMC7367746/>
40. Murovic J, Ding V, Han SS, Adler JR, Chang SD. Impact of CyberKnife Radiosurgery on Overall Survival and Various Parameters of Patients with 1-3 versus  $\geq 4$  Brain Metastases. *Cureus.* 2017 Oct 24;9(10). Available from: </pmc/articles/PMC5741273/>
41. Sedef AM. Pre-Treatment Lymphopenia and NLR May Have Prognostic Value in Turkish High-Grade Glial Tumor Patients. *Eurasian J Med Investig.* 2021;5(1):107–12.
42. Zhang L, Hu Y, Chen W, Tian Y, Xie Y, Chen J. Pre-stereotactic radiosurgery neutrophil-to-lymphocyte ratio is a predictor of the prognosis for brain metastases. *J Neurooncol.* 2020;147(3):691–700. Available from: <https://doi.org/10.1007/s11060-020-03477-w>

43. Mitsuya K, Nakasu Y, Kurakane T, Hayashi N, Harada H, Nozaki K. Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of worse survival after resection in patients with brain metastasis. *J Neurosurg.* 2017;127(2):433–7.
44. Bernardo CD, Cortes-Ortega MD, Nancy RN, Talia WO, Cristian AC, Bargalló-Rocha JE. Association of the neutrophil-to-lymphocyte ratio with brain metastases in Hispanic breast cancer patients. *Cancer Treat Res Commun.* 2021 Jan 1;29:100452.

